Evofem Biosciences Correlations
| EVFMDelisted Stock | USD 0.05 0.0001 0.21% |
The current 90-days correlation between Evofem Biosciences and Tonix Pharmaceuticals Holding is -0.02 (i.e., Good diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evofem Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evofem Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Evofem Biosciences Correlation With Market
Good diversification
The correlation between Evofem Biosciences and DJI is -0.18 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Evofem Biosciences and DJI in the same portfolio, assuming nothing else is changed.
Evofem |
The ability to find closely correlated positions to Evofem Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evofem Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evofem Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evofem Biosciences to buy it.
Moving together with Evofem OTC Stock
Moving against Evofem OTC Stock
| 0.75 | VCEL | Vericel Corp Ord | PairCorr |
| 0.56 | VANI | Vivani Medical | PairCorr |
| 0.39 | VCYT | Veracyte | PairCorr |
| 0.38 | VAXX | Vaxxinity | PairCorr |
| 0.35 | VERA | Vera Therapeutics | PairCorr |
| 0.35 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.31 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.58 | VNDA | Vanda Pharmaceuticals | PairCorr |
| 0.49 | DYAI | Dyadic International | PairCorr |
| 0.45 | VTVT | vTv Therapeutics | PairCorr |
| 0.36 | SRZNW | Surrozen Warrant | PairCorr |
| 0.34 | VRAX | Virax Biolabs Group | PairCorr |
| 0.33 | VSTM | Verastem Upward Rally | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Evofem OTC Stock performing well and Evofem Biosciences OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Evofem Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| TNXP | 5.57 | (1.03) | 0.00 | (0.18) | 0.00 | 14.29 | 34.76 | |||
| SONN | 4.77 | (0.98) | 0.00 | 1.80 | 0.00 | 12.31 | 37.58 | |||
| ONTX | 4.73 | 0.72 | 0.15 | 0.79 | 4.35 | 7.69 | 66.73 | |||
| PALI | 3.48 | (0.33) | 0.00 | 0.54 | 0.00 | 5.97 | 24.25 | |||
| IBIO | 3.77 | 0.54 | 0.12 | 1.29 | 3.54 | 7.76 | 30.48 | |||
| DRUG | 49.10 | 28.20 | 2.94 | (0.78) | 4.39 | 9.23 | 1,471 | |||
| VRAX | 5.67 | (0.89) | 0.00 | 2.19 | 0.00 | 9.65 | 61.28 | |||
| EVFMD | 7.94 | (1.42) | 0.00 | (6.79) | 0.00 | 17.32 | 52.56 | |||
| CALA | 30.35 | 14.62 | 0.45 | (0.85) | 13.88 | 16.67 | 1,016 | |||
| ABEO | 1.99 | 0.16 | 0.04 | 0.38 | 2.29 | 4.31 | 12.28 |
Evofem Biosciences Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Evofem Biosciences otc stock to make a market-neutral strategy. Peer analysis of Evofem Biosciences could also be used in its relative valuation, which is a method of valuing Evofem Biosciences by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Evofem Biosciences Corporate Management
Elected by the shareholders, the Evofem Biosciences' board of directors comprises two types of representatives: Evofem Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evofem. The board's role is to monitor Evofem Biosciences' management team and ensure that shareholders' interests are well served. Evofem Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evofem Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Justin File | Chief Officer | Profile | |
| Katherine Atkinson | Chief Officer | Profile | |
| Saundra Pelletier | Pres Chair | Profile | |
| Amy Raskopf | VP Relations | Profile | |
| Kathy GalloDoyle | VP Sales | Profile | |
| Karina Fedasz | Head Devel | Profile |
Still Interested in Evofem Biosciences?
Investing in delisted otcs can be risky, as the otc stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.